Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
WALTHAM, Mass., Feb. 21, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Raymond James 38th Annual Institutional Investors Conference at the JW Marriott Grand Lakes in Orlando, Florida on Monday, March 6, 2017. Tim Pearson, EVP and CFO of TESARO, will present at 8:40 AM ET and participate in meetings with investors.
- The Barclays Global Healthcare Conference at the Loews Hotel in Miami, Florida on Wednesday, March 15, 2017. Lonnie Moulder, CEO of TESARO, will participate in an analyst-led moderated Q&A from 3:50 to 4:15 PM ET and in meetings with investors.
Live webcasts of the presentations at the Raymond James and Barclays conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
